Medical Advances Get More Chances When Safety Issues Arise
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Withdrawn “me too” NMEs were removed from the market sooner after post-marketing safety signals than first-in-class or advance-in-class NMEs, showing the importance of available alternative therapy (or the lack thereof) in post-marketing risk management decisions.